Published on
Dec 19, 2024
Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation
In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. Novartis confirmed Thursday that it’s closing down MorphoSys sites in Munich and …
Source:
Fierce Pharma
-
Neutral
